I'm not sure at this point but here are some reviews I found.
From the Journal of Antimicrobial Chemotherapy:
..exhibits antibacterial activity against typical respiratory pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and common Gram-negative pathogens. In particular, ceftaroline has activity against resistant Gram-positive cocci, including penicillin- and multidrug-resistant S. pneumoniae, as well as methicillin-resistant S. aureus. The activity of ceftaroline against these phenotypes is attributed to its ability to bind to modified penicillin-binding proteins with high affinity when compared with other β-lactams.
Here's another one from the same journal available as free full text:
..approved in the USA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP).
The spectrum of activity is shown in this table and deserves comment. This spectrum includes organisms outside the approved indications. Of note, on the gram positive side VISA, VRSA, coag negative staph, Listeria and enterococcus (but not VRE) are included. That represents a significant increase in the gram positive spectrum for cephalosporins. On the gram negative side Pseudomonas and ESBL producing organisms are NOT covered, so this is not a big gun for empiric gram negative coverage.
This free full text review contains more detailed pharmacokinetic and pharmacodynamic information which may be helpful in predicting activity against various pathogens in off label clinical situations.